Sandra A. Gardiner - Dec 14, 2021 Form 4 Insider Report for Pulse Biosciences, Inc. (PLSE)

Role
CFO & EVP Admin. and Finance
Signature
/s/ Kenneth B. Stratton, as Attorney-in-Fact
Stock symbol
PLSE
Transactions as of
Dec 14, 2021
Transactions value $
$0
Form type
4
Date filed
2/28/2022, 12:42 PM
Next filing
Jun 3, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PLSE Stock Option (right to buy) Award $0 +26K +100% $0.00 51.9K Dec 14, 2021 Common Stock 26K $13.94 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On November 18, 2019, the reporting person was granted an option to purchase 103,842 shares of the issuer's common stock. The option vests based upon the achievement of performance objectives, with vesting targets no less than 25% vesting per year upon achievement of said objectives established by the Compensation Committee of the issuer, subject to the reporting person's continued service through each vesting date. The performance objectives for 2021 were met, resulting in the vesting of the option as to 25,961 shares.
F2 Represents the options which vested on the 2020 vesting date and the options which vested on the 2021 vesting date.